Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Immunotherapies have transformed cancer care. However, determining who will benefit from these powerful treatment options remains one of the biggest challenges in oncology.

Our elive™ platform is a breakthrough live‑tissue technology designed to predict immunotherapy response with unprecedented precision. The platform is designed to provide functional insights across solid tumor types and immunotherapies. We are seeking qualified laboratory and commercial partners to expand elive™ access internationally.

Ideal partners include: 

• Commercial laboratories expanding into functional and ex vivo testing
•  Laboratories that develop and validate their own advanced assays 
• Pharma and biotech companies developing new immuno-oncology therapies
• Translational or precision oncology research programs